Know Cancer

or
forgot password

An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor


Phase 1
18 Years
N/A
Not Enrolling
Both
Advanced Solid, Malignant Tumors

Thank you

Trial Information

An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor


Inclusion Criteria:



- histological and/or cytological confirmation of a malignant solid tumor

- refractory to standard therapies or for which no appropriate therapies exist

- WHO performance status 0-2

Exclusion Criteria:

- patients with brain tumors or symptomatic cerebral metastases

- systemic anticancer therapy within the last 4 weeks

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Guan Zhongzhen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

SYS Cancer Center

Authority:

China: Food and Drug Administration

Study ID:

D4200L00004

NCT ID:

NCT00503711

Start Date:

September 2006

Completion Date:

November 2007

Related Keywords:

  • Advanced Solid, Malignant Tumors
  • ZD6474 PK
  • Neoplasms

Name

Location